5-years of n-Lorem: What Have We Learned?

Five years of creating medicines, instilling hope, and overcoming steep challenges—all with the singular goal of improving the lives of nano-rare disease patients. Along the way, we’ve proven that WE CAN treat these patients safely and effectively, delivering significant benefit. But what else have we discovered throughout this journey?  Thank you to Hongene Biotech Corporation for sponsoring this 5-Year Anniversary episode.  On This Episode We Discuss: - We CAN do this - n-Lorem is proof of the value of investing in science - We can treat nano-rare patients safely - The nano-rare patient population is large - We must introduce genomic sequencing into newborn evaluation - Most nano-rare diseases are more prevalent than we think - Most diseases are a composite of multiple mutations in one or more genes - A non-profit model in which patients are treated irrespective of their financial status is feasible - Nano-rare mutations are spread throughout the genome - Nano-rare mutations can affect any organ - Essentially all types of mutations can cause nano-rare diseases - Most nano-rare patients express severe, chronic, debilitating, progressive diseases - The journey to diagnosis is often unique, long, and perilous - Significant benefit can be achieved - ASOs administrated intrathecally for CNS diseases can result in profound benefit - ASOs can result in durable benefit - Many patients require allele-selective ASOs - The community is strong - Industrialized processes created by n-Lorem is delivering great value - The modified cross-over clinical design created by n-Lorem is delivering high quality data - If we raise the funds, we can meet the demand Donate: www.nlorem.org/donate